Top-Rated StocksTop-RatedNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $60.14 -0.16 (-0.27%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xenon Pharmaceuticals Stock (NASDAQ:XENE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$60.00▼$61.6350-Day Range$51.21▼$60.3652-Week Range$30.00▼$63.95Volume805,283 shsAverage Volume1.34 million shsMarket Capitalization$5.81 billionP/E RatioN/ADividend YieldN/APrice Target$77.20Consensus RatingBuy Company Overview Xenon Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments. The company’s pipeline comprises multiple preclinical and clinical programs. Its lead asset, XEN1101, is an orally administered potassium channel opener being evaluated for the treatment of focal epilepsy, while other programs target sodium and calcium channel modulators for migraine prophylaxis and pain management. Xenon has established strategic collaborations with academic institutions and contract research organizations to conduct global Phase 1 and Phase 2 studies, with trial sites spanning North America and Europe. Throughout its development efforts, the company leverages translational biomarkers and electrophysiology to guide clinical dosing and patient selection. Founded in 1999 and headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals trades on the Nasdaq under the ticker XENE. Over its history, the company has transitioned from a technology licensee to a fully integrated drug developer, expanding its team of medicinal chemists, pharmacologists and clinical specialists. Xenon is led by President and Chief Executive Officer C. Scott Myers, whose experience in neuroscience drug development supports the company’s mission to advance therapies for patients with unmet medical needs worldwide.AI Generated. May Contain Errors. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreXENE MarketRank™: Xenon Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 191st out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialXenon Pharmaceuticals has a consensus price target of $77.20, representing about 26.2% upside from its current price of $61.17.Amount of Analyst CoverageXenon Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.92) to ($5.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 8.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.75% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 8.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.42 News SentimentXenon Pharmaceuticals has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Xenon Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest7 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $133,488.00 in company stock.Percentage Held by Insiders4.07% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Stock News HeadlinesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJune 25, 2026 | americanbankingnews.comAssessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation EstimateJune 12, 2026 | finance.yahoo.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.July 2 at 1:00 AM | Porter & Company (Ad)Gillian Cannon Sells 1,190 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) StockJune 9, 2026 | insidertrades.comXenon Pharmaceuticals Inc. Rings the Opening BellJune 2, 2026 | nasdaq.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comJPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE)May 24, 2026 | finance.yahoo.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $44.82 on January 1st, 2026. Since then, XENE stock has increased by 36.5% and is now trading at $61.1660. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts' consensus estimates of ($1.17). Read the conference call transcript. When did Xenon Pharmaceuticals IPO? Xenon Pharmaceuticals (XENE) raised $44 million in an initial public offering (IPO) on Friday, October 17th 2014. The company issued 4,000,000 shares at $10.00-$12.00 per share. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings5/07/2026Today7/02/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 3 weeks, XENE's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees210Year Founded1996Price Target and Rating Average Price Target for Xenon Pharmaceuticals$77.20 High Price Target$100.00 Low Price Target$55.00 Potential Upside/Downside+27.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$345.91 million Net MarginsN/A Pretax Margin-4,598.59% Return on Equity-49.23% Return on Assets-46.42% Debt Debt-to-Equity RatioN/A Current Ratio27.79 Quick Ratio27.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book8.02Miscellaneous Outstanding Shares96,666,000Free Float92,732,000Market Cap$5.84 billion OptionableOptionable Beta0.61 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:XENE) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersTrump is positioned. Elon lights the fuse.For a few days, it looked like the whole thing might come apart. And yet… the talks survived. Deconfliction ch...Crypto 101 Media | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
